Panel recommends revised dosing for trial of CF treatment BX004
An independent data monitoring committee, following a safety review, recommended that a Phase 2 trial of BX004, Biomx’s experimental treatment for Pseudomonas aeruginosa infection in people with cystic fibrosis (CF), continue with revised dosing. Although Europe’s part of the study is advancing, the U.S. Food and Drug Administration (FDA)…
